X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
LN-145 is a ready-to-infuse TIL therapy that utilizes an autologous TIL manufacturing process, as originally developed by the NCI and further optimized by Iovance for the treatment of patients with metastatic NSCLC.
Lead Product(s): LN-145
Therapeutic Area: Oncology Product Name: LN-145
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
Details:
Lovance intends to use the proceeds from this offering to support the commercial launch of Amtagvi (lifileucel), which is a tumor-derived autologous T-cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma.
Lead Product(s): Lifileucel
Therapeutic Area: Oncology Product Name: Amtagvi
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Jefferies LLC
Deal Size: $211.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 20, 2024
Details:
Amtagvi (lifileucel) is an engineered tumor-infiltrating lymphocyte (TIL) therapy. It is indicated for the treatment of of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody..
Lead Product(s): Lifileucel
Therapeutic Area: Oncology Product Name: Amtagvi
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2024
Details:
LN-144 (lifileucel) is a tumor infiltrating lymphocyte therapy in combination with pembrolizumab is intended as a treatment for patients with advanced melanoma who progressed on or after prior anti-PD-1/L1 therapy and targeted therapy.
Lead Product(s): Lifileucel,Pembrolizumab
Therapeutic Area: Oncology Product Name: LN-144
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2023
Details:
Iovance intends to use the proceeds to fund preparations for the commercial launch of LN-144 (lifileucel), when approved and to support ongoing clinical programs including its NSCLC registration-directed study and its frontline advanced melanoma Phase 3 confirmatory trial.
Lead Product(s): Lifileucel,Pembrolizumab
Therapeutic Area: Oncology Product Name: LN-144
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Goldman Sachs & Co.
Deal Size: $172.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 13, 2023
Details:
Iovance intends to use the proceeds to fund preparations for the commercial launch of LN-144 (lifileucel), when approved and to support ongoing clinical programs including its NSCLC registration-directed study and its frontline advanced melanoma Phase 3 confirmatory trial.
Lead Product(s): Lifileucel,Pembrolizumab
Therapeutic Area: Oncology Product Name: LN-144
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Goldman Sachs & Co.
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 10, 2023
Details:
LN-145 TIL therapy for patients who have progressed on or after chemotherapy and anti-PD-1 therapy for advanced (unresectable or metastatic) NSCLC without EGFR, ROS or ALK genomic mutations
Lead Product(s): LN-145,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: LN-145
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2023
Details:
LN-144 (lifileucel) is a tumor infiltrating lymphocyte therapy in combination with pembrolizumab is intended as a treatment for patients with advanced melanoma who progressed on or after prior anti-PD-1/L1 therapy and targeted therapy.
Lead Product(s): Lifileucel,Pembrolizumab
Therapeutic Area: Oncology Product Name: LN-144
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2023
Details:
LN-144 (lifileucel) is a tumor infiltrating lymphocyte therapy in combination with pembrolizumab is intended as a treatment for patients with advanced melanoma who progressed on or after prior anti-PD-1/L1 therapy and targeted therapy.
Lead Product(s): Lifileucel
Therapeutic Area: Oncology Product Name: LN-144
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2023
Details:
LN-144 (lifileucel) is a tumor infiltrating lymphocyte therapy in combination with pembrolizumab is intended as a treatment for patients with advanced melanoma who progressed on or after prior anti-PD-1/L1 therapy and targeted therapy.
Lead Product(s): Lifileucel
Therapeutic Area: Oncology Product Name: LN-144
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
